Compare Equinor ASA (EQNR) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs IDEXX Laboratories, Inc. — how do they compare? Equinor ASA trades at $43.02 (market cap $101.62B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: Equinor ASA is far larger — about 2.5× IDEXX Laboratories, Inc.'s market cap, and Equinor ASA pays a 3.63% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EQNR | IDXX | |
|---|---|---|
Market Cap | $101.62B | $40.43B |
Volume | 4,991,782 | 692,164 |
Sector | Energy | Health |
52-Week High | $45.75 | $766.68 |
52-Week Low | $22.41 | $504.70 |
Typical Hold Time | 59 Days | 46 Days |
Enterprise Value | $110.31B | $41.32B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $43.415, up 4.34% with strong technical momentum and bullish moving average signals. The stock shows attractive valuation metrics with P/E of 11.63 and EV/EBITDA of 2.39, while maintaining solid profitability with 21.32% ROE. Recent earnings beat expectations in two of the last three quarters, and the company continues shareholder returns through dividends and buybacks.
EQNR presents compelling value with significant upside to the $87.50 consensus price target, though investors face risks from volatile energy prices and declining profit margins. The company's LNG expansion strategy and strong cash flow generation support long-term growth potential, while technical indicators suggest near-term bullish momentum may continue.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
